Peri, Anna Maria
O’Callaghan, Kevin
Rafiei, Nastaran
Bergh, Haakon
Tabah, Alexis
Chatfield, Mark D
Harris, Patrick NA
Paterson, David L
Article History
Received: 13 November 2023
Accepted: 6 August 2024
First Online: 22 August 2024
Declarations
:
: Approval was granted to this study by the Royal Brisbane and Women’s Hospital Ethics Committee (HREC/2021/QRBW/70126) and ratified by the University of Queensland (2021/HE000073). Patients were enrolled after consent was obtained by study team members from patients or their representatives.
: Not applicable.
: Competing interests: DLP has research funding from Shionogi, Merck, bioMerieux, BioVersys and Pfizer and has received consulting fees from the AMR Action Fund, CARB-X, Aurobac, Pfizer, Merck, Cepheid, bioMerieux and Spero. PNAH reports research grants from Gilead, has served on advisory boards for OpGen, Merck and Sandoz, and has received honoraria from OpGen, Sandoz, Pfizer and bioMerieux. The other authors declare no conflict of interest.